Expert Perspectives: The Why and How for Combination Basal Insulin + GLP-1RA Therapy in Type 2 Diabetes
October 5, 2018
October 4, 2019
Scroll to the Bottom of this Information to Begin this Course
Supported by an educational grant from Novo Nordisk Inc.
- Physicians - maximum of 1.5 ACCME Credit(s)™
- Nurse - 1.5 ANCC contact hours.
- Nurse Practitioner - 1.5 AANP Credit(s).
- Pharmacist - 1.5 ACPE Credit(s)
All other health care professionals completing this course will be issued a statement of participation.
This activity is intended for primary care physicians, endocrinologists, nurse practitioners, nurses, pharmacists, and other clinicians with an interest in type 2 diabetes.
Statement of Need/Program Overview
John Anderson, MD, and Vivian Fonseca, MD, provide their clinical insights into the rapidly evolving use of combined basal insulin and glucagon-like peptide-1 receptor agonist (GLP-1RA) therapy for the treatment of patients with type 2 diabetes mellitus (T2DM). Based upon the pathophysiologic rationale for combining basal insulin and a GLP-1RA, Drs. Anderson and Fonseca discuss the benefits and limitations of adding a GLP-1RA vs prandial insulin in patients with inadequate glycemic control with basal insulin.
Upon completion of this activity, participants should be able to:
- Describe the unmet needs of patients with type 2 diabetes
- Outline the role of basal insulin and GLP-1RAs as described in current guidelines
- Compare the benefits and limitations of GLP-1RA vs prandial insulin as add-on to basal insulin
- Describe the glycemic and nonglycemic outcomes observed with fixed-ratio basal insulin/GLP-1RA combination products
- Initiate and titrate fixed-ratio basal insulin/GLP-1RA combination products
John E. Anderson, MD
The Frist Clinic
Vivian A. Fonseca, MD
Professor of Medicine and Pharmacology
Assistant Dean for Clinical Research
Tullis-Tulane Alumni Chair in Diabetes
Chief, Section of Endocrinology
Tulane University Health Sciences Center
New Orleans, Louisiana
The Annenberg Center for Health Sciences at Eisenhower is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.
The Annenberg Center for Health Sciences at Eisenhower designates this enduring material for a maximum of 1.5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
The Annenberg Center for Health Sciences at Eisenhower is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education. This program has been assigned ACPE Universal Program # 0797-0000-18-063-H01-P. This program is designated for up to 1.5 contact hours (0.15 CEUs) of continuing pharmacy education credit. This activity will address professional practice gaps in knowledge.
Annenberg Center for Health Sciences at Eisenhower is accredited by the American Association of Nurse Practitioners as an approved provider of nurse practitioner continuing education. Provider number: 040207. This program is accredited for 1.5 contact hours. Program ID #5651.
Annenberg Center for Health Sciences is accredited as a provider of continuing nursing education by the American Nurses Credentialing Center's Commission on Accreditation.
A maximum of 1.5 contact hours may be earned for successful completion of this activity.
Provider is approved by the California Board of Registered Nursing, Provider #13664, for 1.5 contact hours. To receive credit for education contact hours outside of the state of California, please check with your state board of registered nursing for reciprocity.
Certificates will be available online at the Web address noted on the evaluation. For Pharmacists and Pharmacy Technologists- Transcript information will be available at www.mycpemonitor.net within 4 weeks.
Disclosures of Conflicts of Interest
Vivian A. Fonseca, MD
- Research Consultant: Bayer, Boehringer Ingelheim
- Consultant: Asahi, AstraZeneca, Eli Lilly, Intarcia, Novo Nordisk, Sanofi-Aventis, Takeda
John E. Anderson, MD
- Consultant: Abbot, AstraZeneca, Boehringer Ingelheim, Eli Lilly, Janssen, Merck, Novo Nordisk, Sanofi
- Speakers Bureau: AstraZeneca, Boehringer Ingelheim, Eli Lilly, Janssen, Sanofi
- Shareholder: NuSirt Biopharma
All clinical topics for Vivian Fonseca, MD, and John Anderson, MD, above, are diabetes.
Additional content planners:
The following have no significant relationship to disclose:
Gregory Scott, PharmD (medical writer)
Heather Gibson, BSN, MSN (peer reviewer)
Christopher Flores, MD (peer reviewer)
Annenberg Center for Health Sciences:
Charles Willis, Director of Continuing Education, consults for Pfizer, Inc; all other staff at the Annenberg Center for Health Sciences at Eisenhower have no relevant commercial relationships to disclose.
Instruction for Participation and Credit
This activity is an online enduring material. Successful completion is achieved by reading and/or viewing the material(s), reflecting on its implications in your practice, and completing the assessment component.
Hardware and Software Requirements
This site is best viewed with an HTML5 compatible browser, this list includes the versions of Mircrosoft Internet Explorer, Mozilla Firefox, Google Chrome, and Apple's Safari. You can visit the independent (3rd party) site www.whatismybrowser.com to determine if you have the latest version of your browser. Certain educational activities may require additional software to view multimedia, presentation, or printable versions of their content. That software may be: Adobe Flash, Apple Quicktime, Adobe Acrobat, Microsoft Powerpoint, Windows Media Player, and Real Networks Real One Player.
Disclosure of Unlabeled User
The faculty for this activity have disclosed that there will be no discussion about the use of products for non-FDA approved applications.
The ideas and opinions presented in this educational activity are those of the faculty and do not necessarily reflect the views of the Annenberg Center and/or its agents. As in all educational activities, we encourage practitioners to use their own judgment in treating and addressing the needs of each individual patient, taking into account that patient’s unique clinical situation. The Annenberg Center disclaims all liability and cannot be held responsible for any problems that may arise from participating in this activity or following treatment recommendations presented.